[EN] INHIBITING OTUB1<br/>[FR] INHIBITION DE L'OTUB1
申请人:INTEGRAL EARLY DISCOVERY INC
公开号:WO2020223551A1
公开(公告)日:2020-11-05
The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of OTUB1. The compounds are further useful in the inhibition of OTUB1 and the treatment of diseases or disorders associated with the inhibition of OTUB1. For instance, the disclosure is concerned with compounds and compositions for inhibition of OTUB1, methods of treating diseases associated with the inhibition of OTUB1 (e.g., inflammatory diseases like irritable bowel disease and Lupus), and methods of synthesis of these compounds.
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A
1
and A
2
are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A
1
and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
申请人:Singh Rajinder
公开号:US20110105512A1
公开(公告)日:2011-05-05
Bridged bicyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase AxI. Methods of using the compounds in treating diseases or conditions associated with AxI activity are also disclosed.
NOVOLAC-BASED EPOXY COMPOUND, PRODUCTION METHOD FOR SAME, COMPOSITION AND CURED ARTICLE COMPRISING SAME, AND USE FOR SAME
申请人:Korea Institute of Industrial Technology
公开号:EP2871182A1
公开(公告)日:2015-05-13
The present invention relates to: a novolac-based epoxy compound having an alkoxysilyl group, which compound does not require a separate silane coupling agent and exhibits a low coefficient of thermal expansion (CTE) and high glass transition in a synergistic effect, when forming a composite material by curing; a production method for same; and an epoxy composition and cured article comprising same. According to one mode of embodiment of the present invention, provided are: a novolac-based epoxy compound having an alkoxysilyl group of chemical formula I-1 to I-4; a production method for a novolac-based epoxy compound having an alkoxysilyl group of chemical formula I-1 to 1-4 by means of the epoxidation, alkenylation and alkoxysilylation of a novolac-based epoxy compound; a production method for a novolac-based epoxy compound having an alkoxysilyl group of chemical formula I-1 to 1-4 by means of the epoxidation and alkoxysilylation of a novolac-based epoxy compound; and an epoxy composition comprising a novolac-based epoxy compound having an alkoxysilyl group of chemical formula I-1 to I-4; and also provided is a cured article of same. A cured article constituted by a composite article of the composition comprising the novolac-based epoxy compound having an alkoxysilyl group of a novel kind according to the present invention has improved chemical bonding efficiency when forming an epoxy composite by means of chemical bonding between the alkoxysilyl groups of the epoxy compound having alkoxysilyl groups, not to mention chemical bonding of a filler with the alkoxysilyl groups in the epoxy compound. Consequently, a low CTE and high glass transition temperature are exhibited.